News

Cipla Ltd. announced that its Operations and Administrative Committee has allotted 5,281 fully paid-up equity shares of INR 2 each under the Employee Stock Option Scheme 2013 -A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the company’s issued, subscribed and paid-up share capital to INR 1,61,57,16,894 comprising of 80,78,58,447 equity shares.

A court order has paved the way for the amalgamation of a wholly-owned subsidiary into its parent company, streamlining the merger process under Company Application No. 114/2026. The scheme, involving the Transferor Company merging into the Transferee Company, does not necessitate the issuance of new shares or negatively impact creditors, leading the court to dispense with shareholder and creditor meetings of the Transferee Company, citing precedents like *Mahaamba Investments Limited*. While meetings are waived, the Transferee Company must still provide notice to shareholders, creditors, and regulatory bodies via various channels, allowing a 30-day period for objections. The Applicant Companies are also required to file details regarding corporate guarantees, pending legal cases, and letters of credit, and post the scheme on their website, followed by an affidavit of service within 10 working days.

Cipla announced that its wholly owned subsidiary, InvaGen Pharmaceuticals (InvaGen) has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection of its manufacturing facility located at Hauppauge, Long Island, New York, USA.

The board of Cipla at its meeting held on 23 July 2026 has approved the following:Transition of Ashish Adukia, Global Chief Financial Officer, to internal business leadership role. Consequent to such transition, Ashish Adukia has relinquished the position as the Global Chief Financial Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of 23 July 2026. Appointment of Dinesh Jain, Chief - Corporate Finance, as Global Chief Financial Officer and KMP with effect from 24 July 2026.

Cipla has granted 24,709 stock options and employee stock appreciation rights on 23 July 2026.